Targeting conventionally intractable cancer-driving proteins: What has been achieved recently?
Despite being appealing oncological targets, a majority of cancer-driving proteins with high biomedical relevance remain intractable to conventional small-molecule drug design due to several well-documented challenges. Nonetheless, progress in drug design strategies and experimental techniques has produced far-reaching...